Boxer Capital Management, LLC, by Aaron I Davis, Managing Member
@Boxer Capital, Llc
Latest period2024 - Q3ReportedManaged Assets$2.038BTotal holdings68
Assets growth rate7.32%Assets growth rate (2-Q avg)0.55%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Boxer Capital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 68 positions.
Assets under management
The assets under management (AUM) of Boxer Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.038B in assets, with a quarterly growth rate of 7.32% and a 2-quarter average growth rate of 0.55%. The portfolio is managed by Boxer Capital Management, LLC, by Aaron I Davis, Managing Member, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
ORICOric Pharmaceuticals Inc
| 0.88% | $17.759M 1.733M shares@ $10.26 avg price | |
GPCRStructure Therapeutics Inc
| 0.87% | $17.556M 400,000 shares@ $43.89 avg price | |
FATEFate Therapeutics Inc
| 0.86% | $17.363M 4.961M shares@ $3.5 avg price | Decreased -39.61% |
ELVNEnliven Therapeutics Inc
| 0.85% | $17.146M 671,358 shares@ $25.54 avg price | |
REPLReplimune Group Inc
| 0.83% | $16.838M 1.536M shares@ $10.96 avg price | |
DAWNDay One Biopharmaceuticals I
| 0.82% | $16.576M 1.19M shares@ $13.94 avg price | |
CGEMCullinan Therapeutics
| 0.75% | $15.198M 907,895 shares@ $16.74 avg price | Increased 38% |
ARVNArvinas Inc
| 0.74% | $14.99M 608,614 shares@ $24.64 avg price | |
CLYMEliem Therapeutics Inc
| 0.66% | $13.25M 2.603M shares@ $5.09 avg price | |
RLAYRelay Therapeutics Inc
| 0.64% | $12.879M 1.819M shares@ $7.09 avg price |